Meta-Analysis: GnRH Analog Preserves Ovarian Function in Early Breast Cancer

In this video, Halle C. F. Moore, MD, of the Cleveland Clinic in Ohio, discusses a meta-analysis that looked at five studies testing the use of a gonadotropin-releasing hormone (GnRH) analog to protect ovarian function and preserve fertility in premenopausal women undergoing chemotherapy for early-stage breast cancer.

Moore was one of the authors of the study (abstract GS4-01), which was presented last week at the 2017 San Antonio Breast Cancer Symposium (SABCS), held December 5–9 in San Antonio, Texas.